Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, China.
J Gastroenterol Hepatol. 2020 May;35(5):896-904. doi: 10.1111/jgh.15012. Epub 2020 Feb 28.
The prophylactic effect of nonselective nonsteroidal anti-inflammatory drugs on post-ERCP (endoscopic retrograde cholangiopancreatography) pancreatitis has been observed for a long time. However, whether the selective nonsteroidal anti-inflammatory drugs possess similar abilities and the mechanisms by which nonsteroidal anti-inflammatory drugs work remain unclear. The present study aimed to determine the protective effects of nonsteroidal anti-inflammatory drugs on post-ERCP pancreatitis in a rat model and examine underlying mechanisms.
Thirty-two female rats were equally and randomly divided into four groups: the sham group, post-ERCP pancreatitis model group, indomethacin-pretreated group, and parecoxib-pretreated group. Indomethacin or parecoxib was delivered 30 min prior to surgery; 24 h after post-ERCP pancreatitis establishment, the rats were sacrificed. Serum amylase and lipase activities, inflammatory cytokine release, pancreatic histopathological scores, neutrophil infiltration, and the expression pattern cyclooxygenase at the protein level and pancreatic apoptosis were quantified and analyzed.
Both indomethacin and parecoxib inhibited the activities of serum amylase and lipase and reduced the severity of pancreatic histopathology. Mechanistically, both drugs decreased the expression level of cyclooxygenase 2; however, they had no influence on the cyclooxygenase 1 protein level. Moreover, they reduced inflammatory cytokine release, neutrophil infiltration into the pancreas, and NF-κB p65 activation. Notably, we found that apoptotic cells in the pancreas were remarkably diminished after the administration of both nonsteroidal anti-inflammatory drugs.
Both selective and nonselective nonsteroidal anti-inflammatory drugs exert protective effects against post-ERCP pancreatitis by restraining inflammation and reducing acinar cell apoptosis through the inhibition of cyclooxygenase 2.
非选择性非甾体抗炎药(NSAIDs)预防内镜逆行胰胆管造影(ERCP)后胰腺炎的作用已被长期观察到。然而,选择性 NSAIDs 是否具有类似的作用,以及 NSAIDs 发挥作用的机制尚不清楚。本研究旨在确定 NSAIDs 在大鼠 ERCP 后胰腺炎模型中的保护作用,并探讨其潜在机制。
将 32 只雌性大鼠等分为 4 组:假手术组、ERCP 后胰腺炎模型组、吲哚美辛预处理组和帕瑞昔布预处理组。吲哚美辛或帕瑞昔布在手术前 30 分钟给药;在建立 ERCP 后胰腺炎 24 小时后,处死大鼠。检测血清淀粉酶和脂肪酶活性、炎症细胞因子释放、胰腺组织病理评分、中性粒细胞浸润以及 COX 蛋白表达水平和胰腺细胞凋亡情况。
吲哚美辛和帕瑞昔布均抑制了血清淀粉酶和脂肪酶的活性,减轻了胰腺组织病理损伤。机制上,两种药物均降低了 COX-2 的表达水平,但对 COX-1 蛋白水平无影响。此外,它们还降低了炎症细胞因子的释放、中性粒细胞浸润和 NF-κB p65 的激活。值得注意的是,我们发现两种 NSAIDs 给药后,胰腺中的凋亡细胞明显减少。
选择性和非选择性 NSAIDs 均可通过抑制 COX-2 来减轻炎症反应和减少腺泡细胞凋亡,从而对 ERCP 后胰腺炎发挥保护作用。